25 mCi 177Lu- DTPA-omburtamab

Phase 1

25 mCi 177Lu- DTPA-omburtamab is one of 8 therapeutic programs targeting Recurrent Medulloblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent MedulloblastomaRecruiting

Recurrent MedulloblastomaPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Recurrent Medulloblastoma

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 2

1 2

Avastin

Roche

Phase 2

1 3

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 4

Triostat

VViking Therapeutics, Inc.

Phase 2

1 5

Decadron

AAspen Global Incorporated

Phase 2

1 6

Antihistamine

Arrowhead Pharmaceuticals

Phase 2

1 7

Antipyretic

Ultragenyx

Phase 2

1 8

25 mCi 177Lu- DTPA-omburtamab

MMemorial Sloan Kettering Cancer Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1Recruiting

Recurrent Medulloblastoma

NCT07698899

Clinical

Trials by Indication[1]

Recurrent Medulloblastoma1 trial

A Phase I Dose Escalation Trial of Compartmental Radioimmunotherapy (cRIT) Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory B7H3 Expressing Primary or Metastatic CNS Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07698899·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 25 mCi 177Lu- DTPA-omburtamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 25 mCi 177Lu- DTPA-omburtamab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: MMemorial Sloan Kettering Cancer Center

25 mCi 177Lu- DTPA-omburtamab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Recurrent Medulloblastoma1 trial

References

Drug Info

Quick Facts

Related News